CoChat
Sign Up
Cited by 24Hepatitis C virus researchOrgan Transplantation Techniques and OutcomesHepatocellular Carcinoma Treatment and Prognosis

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Decreasing frequency and improved outcomes of hepatitis C‐related liver transplantation in the era of direct‐acting antivirals – a retrospective cohort study

Arora, Sumant S., Axley, Page, Ahmed, Zunirah, Satapathy, Sanjaya K., Wong, Robert, Kuo, Young‐Fang, Singal, Ashwani K.·2019·Transplant International
DOI 10.1111/tri.13424
Open this paper in CoChat — free account

Abstract

Benefit of direct-acting antivirals (DAA) for hepatitis C virus (HCV) on clinical outcomes is unclear. We examined temporal trends in liver transplant (LT) listings, receipt of LT, re-LT, and survival between pre-DAA (2009-2012) and DAA era (2013-2016) using UNOS database. Of 32 319 first adult LT, 15 049 (47%) were performed for HCV. Trends on listing, first LT, and of re-LT for HCV showed 23%, 20%, and 21% decrease in DAA compared to pre-DAA era (P < 0.0001). One-year liver graft and patient survival among HCV LT improved in DAA era (90% vs. 86% and 92% vs. 88%, respectively, P < 0.0001). Non-HCV LT showed no improvement in survival (89% vs. 89% and 92% vs. 92.4%, P = NS). On cox regression, compared to non-HCV LTs in DAA era, LT for HCV in pre-DAA era had worse patient survival (HR 1.56 [1.04-2.35]). The outcome was similar when compared to LTs for HCV in DAA era and for non-HCV in pre-DAA era. Burden of HCV-related LT waitlist and LT is declining in DAA era, with improved post-transplant outcomes, more so in later than earlier DAA era. Our findings negate recent Cochrane meta-analysis on DAA therapy and encourage studies to examine HCV clinical outcomes outside LT setting.

Overview

Integrity signals

Registry

Crossref · 10.1111/tri.13424

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 35

  1. Edlin BR, 2015, Toward a more accurate estimate of the prevalence of hepatitis C in the United States, Hepatology, 62, 1353, 10.1002/hep.27978 · DOI
  2. Ditah I, 2014, The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010, J Hepatol, 60, 691, 10.1016/j.jhep.2013.11.014 · DOI
  3. Armstrong GL, 2006, The prevalence of hepatitis C virus infection in the United States, 1999 through 2002, Ann Intern Med, 144, 705, 10.7326/0003-4819-144-10-200605160-00004 · DOI
  4. Udompap P, 2016, Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection, J Hepatol, 64, 1027, 10.1016/j.jhep.2016.01.009 · DOI
  5. Smith MR, 2011, Combined liver and kidney transplantation: a single centre experience, Hepatology, 54, 660
  6. Razavi H, 2013, Chronic hepatitis C virus (HCV) disease burden and cost in the United States, Hepatology, 57, 2164, 10.1002/hep.26218 · DOI · Paper page
  7. Dultz G, 2017, Liver transplantation for chronic hepatitis C virus infection in the United States 2002–2014: an analysis of the UNOS/OPTN registry, PLoS ONE, 12, e0186898, 10.1371/journal.pone.0186898 · DOI
  8. Wolfe RA, 2010, Trends in organ donation and transplantation in the United States, 1999‐2008, Am J Transplant, 10, 961, 10.1111/j.1600-6143.2010.03021.x · DOI
  9. Ly KN, 2016, Rising mortality associated with hepatitis C virus in the United States, 2003–2013, Clin Infect Dis, 62, 1287, 10.1093/cid/ciw111 · DOI · Paper page
  10. Setiawan VW, 2016, Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort, Hepatology, 64, 1969, 10.1002/hep.28677 · DOI
  11. Goldberg D, 2017, Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation, Gastroenterology, 152, 1090 e1, 10.1053/j.gastro.2017.01.003 · DOI
  12. Wong RJ, 2015, Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States, Gastroenterology, 148, 547, 10.1053/j.gastro.2014.11.039 · DOI
  13. Beste LA, 2015, Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013, Gastroenterology, 149, 1471, 10.1053/j.gastro.2015.07.056 · DOI
  14. Goldberg D, 2016, Patients with hepatocellular carcinoma have highest rates of wait‐listing for liver transplantation among patients with end‐stage liver disease, Clin Gastroenterol Hepatol, 14, 1638 e2, 10.1016/j.cgh.2016.06.019 · DOI
  15. Chhatwal J, 2016, Hepatitis C disease burden in the United States in the era of oral direct‐acting antivirals, Hepatology, 64, 1442, 10.1002/hep.28571 · DOI
  16. Foster GR, 2016, Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis, J Hepatol, 64, 1224, 10.1016/j.jhep.2016.01.029 · DOI
  17. Cheung MCM, 2016, Outcomes after successful direct‐acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis, J Hepatol, 65, 741, 10.1016/j.jhep.2016.06.019 · DOI
  18. Meer AJ, 2012, Association between sustained virological response and all‐cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, JAMA, 308, 2584, 10.1001/jama.2012.144878 · DOI
  19. D'Amico G, 2011, Liver or combined liver‐kidney transplantation for autosomal dominant polycystic kidney disease, Liver Transpl, 17, S282
  20. Flemming JA, 2017, Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy, Hepatology, 65, 804, 10.1002/hep.28923 · DOI
  21. Belli LS, 2016, Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study, J Hepatol, 65, 524, 10.1016/j.jhep.2016.05.010 · DOI
  22. Kim WR, 2009, Trends in waiting list registration for liver transplantation for viral hepatitis in the United States, Gastroenterology, 137, 1680, 10.1053/j.gastro.2009.07.047 · DOI
  23. Crespo G, 2018, The efficacy of direct anti‐HCV drugs improves early post‐liver transplant survival and induces significant changes in waiting list composition, J Hepatol, 69, 11, 10.1016/j.jhep.2018.02.012 · DOI
  24. Jakobsen JC, 2017, Direct‐acting antivirals for chronic hepatitis C, Cochrane Database Syst Rev, 9, CD012143
  25. Buonaccorsi JP, 2014, On the power of the Cochran‐Armitage test for trend in the presence of misclassification, Stat Methods Med Res, 23, 218, 10.1177/0962280211406424 · DOI
  26. Poordad F, 2011, Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med, 364, 1195, 10.1056/NEJMoa1010494 · DOI
  27. Jacobson IM, 2011, Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med, 364, 2405, 10.1056/NEJMoa1012912 · DOI
  28. Feld JJ, 2015, Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection, N Engl J Med, 373, 2599, 10.1056/NEJMoa1512610 · DOI
  29. Yau AH, 2014, Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all‐oral interferon‐free antiviral regimens: a concise review, Can J Gastroenterol Hepatol, 28, 445, 10.1155/2014/549624 · DOI
  30. Schinazi R, 2014, HCV direct‐acting antiviral agents: the best interferon‐free combinations, Liver Int, 34, 69, 10.1111/liv.12423 · DOI
  31. Manns M, 2014, Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment‐naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‐2): a randomised, double‐blind, placebo‐controlled phase 3 trial, Lancet, 384, 414, 10.1016/S0140-6736(14)60538-9 · DOI
  32. Afdhal N, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N Engl J Med, 370, 1889, 10.1056/NEJMoa1402454 · DOI
  33. Liang TJ, 2013, Current and future therapies for hepatitis C virus infection, N Engl J Med, 368, 1907, 10.1056/NEJMra1213651 · DOI
  34. Lawitz E, 2013, Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, 1878, 10.1056/NEJMoa1214853 · DOI
  35. Fried MW, 2013, Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naive genotype 1 hepatitis C: the randomized PILLAR study, Hepatology, 58, 1918, 10.1002/hep.26641 · DOI

Cited by

Sorted by citations

Metadata

Authors
Arora, S. S., Axley, P., Ahmed, Z., Satapathy, S. K., Wong, R., Kuo, Y., & Singal, A. K.
Affiliations
  • University of Iowa (US)
  • University of Alabama at Birmingham (US)
  • University of Tennessee Health Science Center (US)
  • Alameda Health System (US)
  • The University of Texas Medical Branch at Galveston (US)
  • University of South Dakota (US)
ORCID
Venue
Transplant International
Publisher
Frontiers Media SA
Published
2019-03-26
Volume
32
Issue
8
Pages
854-864
ISSN
  • 0934-0874 (ISSN-L)
  • 1432-2277
DOI
10.1111/tri.13424
OpenAlex
W2921118528
Cited by
24
References
1
Citations by year
2026: 1 · 2024: 2 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 2
FWCI
2.39
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
Locations
  • Transplant International (publishedVersion)
  • PubMed (publishedVersion)
Funders
American College of Gastroenterology
Topics
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords
hepatitis C virus, liver transplantation, direct-acting antivirals, transplant waiting list, retransplantation, graft survival, patient survival, temporal trends, HCV-related liver disease
MeSH terms
Adult, Antiviral Agents, Female, Graft Survival, Carcinoma, Hepatocellular, Humans, Immunosuppression Therapy, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Tissue and Organ Procurement, Registries, Reoperation, Retrospective Studies, Time Factors, Waiting Lists, Proportional Hazards Models, Liver Transplantation, Hepacivirus, Treatment Outcome, Hepatitis C, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review